HC Wainwright Cuts Imunon (NASDAQ:IMNN) Price Target to $12.00

Imunon (NASDAQ:IMNN) had its price target trimmed by HC Wainwright from $14.00 to $12.00 in a report issued on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Price Performance

Shares of NASDAQ IMNN opened at $0.75 on Monday. The stock’s 50-day moving average is $1.00 and its two-hundred day moving average is $1.19. Imunon has a 1-year low of $0.48 and a 1-year high of $3.65. The company has a market cap of $44.84 million, a price-to-earnings ratio of -0.40 and a beta of 2.14.

Imunon (NASDAQ:IMNN) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.04. Equities research analysts anticipate that Imunon will post -1.68 earnings per share for the current fiscal year.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.